Oral Presentation

Deep responses following treatment with loncastuximab tesirine in patients with relapsed/refractory including those with high-risk, TP53-altered Waldenström macroglobulinemia

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver
MENU